Optimization of NULOJIX (Belatacept) Usage as a Means of Minimizing CNI Exposure in Simultaneous Pancreas and Kidney Transplantation (CTOT-15)

This study is a multicenter, prospective, randomized (1:1), open-label, Phase II study to compare a NULOJIX (belatacept) based immunosuppressive regimen to a CNI-based regimen in recipients of SPK. Subjects will be consented and enrolled until a total of 60 subjects are randomized.